en.Wedoany.com Reported - On June 9, British pharmaceutical company GlaxoSmithKline (GSK) is in talks to acquire Nuvalent, a US cancer drug developer, for over $9 billion. The two sides aim to reach an agreement within this week, but the deal has not yet been officially announced and ultimately depends on the progress of negotiations and the confirmation of conditions near the signing stage.
This potential acquisition points to GSK's efforts to strengthen its oncology drug pipeline. Nuvalent, headquartered in Cambridge, Massachusetts, USA, is a clinical-stage biopharmaceutical company focused on developing precision therapies targeting validated kinase targets in cancer. The company's current core assets are concentrated in non-small cell lung cancer (NSCLC), including zidesamtinib for ROS1-positive NSCLC and neladalkib for ALK-positive NSCLC. Nuvalent previously disclosed that the new drug application (NDA) for zidesamtinib is under review by the U.S. Food and Drug Administration (FDA), with a target action date of September 18, 2026; neladalkib has also submitted an NDA for ALK-positive advanced NSCLC following treatment with tyrosine kinase inhibitors. This means that if GSK completes the acquisition, it will gain oncology drug candidate assets close to key regulatory milestones, rather than just early-stage research projects.
Nuvalent's recent market capitalization is approximately $7 billion. A potential acquisition valuation in the range of $9 billion to $10 billion would reflect a significant transaction premium.
GSK has been adjusting its R&D focus in recent years, with oncology being one of its core areas for renewed strengthening. Large pharmaceutical companies supplement their pipelines through M&A, often driven by patent cycles, growth pressures on core products, and commercialization windows for new drugs. Compared to nurturing assets from internal early-stage R&D, acquiring late-stage or near-filing biotech companies can more quickly replenish revenue growth sources for the coming years. Nuvalent's projects focus on molecularly defined subgroups of lung cancer patients, featuring precision therapy, differentiated targeting, and potential demand for later-line treatments, aligning with large pharma's direction in seeking high-value, registrable, and scalable assets in oncology.
If the deal materializes, it will become one of GSK's largest acquisitions in over a decade and will further change the external perception of its oncology business. GSK has historically had strong accumulations in vaccines, respiratory, immunology and inflammation, HIV, and infectious diseases, while its oncology business has undergone asset adjustments and restructuring. The addition of Nuvalent is expected to provide GSK with more direct late-stage clinical assets in the precision treatment of NSCLC, and offer new leverage for subsequent indication expansion, combination therapies, and commercial team building. The global pharmaceutical industry is currently seeing increased M&A activity, and oncology companies with clear clinical data, regulatory milestones, and commercialization potential remain key targets for large pharma competition.
Next, whether the deal will be signed within this week will be the first focal point for the market. If the two sides formally reach an agreement, subsequent procedures will involve shareholders, regulatory and antitrust reviews, and will depend on the outcomes of Nuvalent's core drug reviews. For GSK, the ultimate value of this deal will depend not only on the acquisition price but also on whether the relevant drug candidates can be successfully approved, whether they can enter key treatment pathways post-launch, and whether the oncology pipeline can sustain expansion capabilities.
This article is compiled by Wedoany. All AI citations must indicate the source as "Wedoany". If there is any infringement or other issues, please notify us promptly, and we will modify or delete it accordingly. Email: news@wedoany.com
